All In Biotech

Drug Trial Radar · NCT07053423

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Mucus Plugging and Other Lung Imaging Parameters in Patients With Chronic Obstructive Pulmonary Disease.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Sep 22, 2025

Primary completion

Dec 23, 2028

Study completion Feb 2, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive). Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The number of visits will be 9.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • DupilumabDrug

    Pharmaceutical form:Solution for injection-Route of administration:SC injection

  • PlaceboDrug

    Pharmaceutical form:Solution for injection-Route of administration:SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Week 24 in global lung mucus score (UCSF mucus scoring)Time frame: Baseline to Week 24

Locations

85 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - School of Medicine- Site Number : 8400003

    Birmingham, Alabama · Recruiting

  • University of Miami Dermatology Clinical Trials Unit- Site Number : 8400015

    Miami, Florida · Recruiting

  • Finlay Medical Research- Site Number : 8400010

    Miami, Florida · Recruiting

  • Private Practice - Dr. David Kavtaradze- Site Number : 8400017

    Cordele, Georgia · Recruiting

  • University of Kansas Medical Center- Site Number : 8400005

    Kansas City, Kansas · Recruiting

  • Johns Hopkins Bayview Medical Center- Site Number : 8400009

    Baltimore, Maryland · Recruiting

  • Brigham & Women's Hospital- Site Number : 8400014

    Boston, Massachusetts · Recruiting

  • American Health Research - Charlotte- Site Number : 8400013

    Charlotte, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Pulmonary, Sleep And Allergy- Site Number : 8400004

    Winston-Salem, North Carolina · Recruiting

  • Clinical Research Associates of Central Pennsylvania- Site Number : 8400002

    DuBois, Pennsylvania · Recruiting

  • REX Clinical Trials - Beaumont- Site Number : 8400011

    Beaumont, Texas · Recruiting

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320001

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • Investigational Site Number : 0400005

    Linz, Austria · Recruiting

  • Hospital Beneficência Portuguesa de São Paulo- Site Number : 0760006

    São Paulo, Brazil · Recruiting

  • Incor - Instituto do Coracao- Site Number : 0760001

    São Paulo, Brazil · Recruiting

  • Hospital Dom Pedro De Alcantara- Site Number : 0760009

    Feira de Santana, Estado de Bahia, Brazil · Recruiting

  • Associacao Proar- Site Number : 0760005

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Clínica CLARE- Site Number : 0760004

    Goiânia, Goiás, Brazil · Recruiting

  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760002

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Investigational Site Number : 1240005

    Calgary, Alberta, Canada · Recruiting

  • Investigational Site Number : 1240002

    London, Ontario, Canada · Recruiting

  • Investigational Site Number : 1560005

    Chengdu, China · Recruiting

  • Investigational Site Number : 1560013

    Guangzhou, China · Recruiting

  • Investigational Site Number : 1560001

    Guangzhou, China · Recruiting

  • Investigational Site Number : 1560004

    Hangzhou, China · Recruiting

  • Investigational Site Number : 1560010

    Harbin, China · Recruiting

  • Investigational Site Number : 1560012

    Ningbo, China · Recruiting

  • Investigational Site Number : 1560009

    Xiamen, China · Recruiting

  • Investigational Site Number : 2080003

    Aalborg, Denmark · Recruiting

  • Investigational Site Number : 2080002

    Vejle, Denmark · Recruiting

  • Investigational Site Number : 2500008

    La Tronche, France · Recruiting

  • Investigational Site Number : 2500001

    Lille, France · Recruiting

  • Investigational Site Number : 2500005

    Lyon, France · Recruiting

  • Investigational Site Number : 2500006

    Marseille, France · Recruiting

  • Investigational Site Number : 2500002

    Montpellier, France · Recruiting

  • Investigational Site Number : 2500003

    Pessac, France · Recruiting

  • Investigational Site Number : 2500004

    Reims, France · Recruiting

  • Investigational Site Number : 2760003

    Berlin, Germany · Recruiting

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.